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Intravesical instillation of Mycobacterium bovis bacillus Calmette-Gu´ erin (BCG) has been used for treating bladder cancer for
3 decades. However, BCG therapy is ineﬀective in approximately 30–40% of cases. Since evidence supports the T helper type 1
(Th1) response to be essential in BCG-induced tumor destruction, studies have focused on enhancing BCG induction of Th1
immune responses. Although BCG in combination with Th1 cytokines (e.g., interferon-α) has demonstrated improved eﬃcacy,
combination therapy requires multiple applications and a large quantity of cytokines. On the other hand, genetic manipulation
of BCG to secrete Th1 cytokines continues to be pursued with considerable interest. To date, a number of recombinant BCG
(rBCG) strains capable of secreting functional Th1 cytokines have been developed and demonstrated to be superior to BCG. This
paper discusses current rBCG research, concerns, and future directions with an intention to inspire the development of this very
promising immunotherapeutic modality for bladder cancer.
1. ClinicalUse of BCG in
Bladder Cancer Treatment
Urothelial carcinoma of the bladder is the second most
common urologic neoplasm after prostate carcinoma in the
UnitedStates,withanestimated70,530newcasesand14,680
deaths in 2010 [1]. Global prevalence of bladder cancer is
estimated at >1 million and is steadily increasing. At the time
of diagnosis, 20–25% of cases are muscle invasive (stage T2
or higher) and are typically treated with surgical resection
(radical cystectomy) [2]. The remainders are nonmuscle
invasivebladdercancer(NMIBC)includingtumorsconﬁned
to the epithelial mucosa (Ta), tumors invading the lamina
propria (T1), and carcinoma in situ (Tis). Transurethral
resection of bladder tumor (TURBT) is the primary treat-
ment for Ta and T1 lesions. Intravesical therapy is used as
adjuvant treatment to prevent recurrence and progression of
the disese after TURBT and is also the treatment of choice
for carcinoma in situ. Intravesical administration of BCG, a
live attenuated strain of Mycobacterium bovis widely used as
a vaccine against tuberculosis, is currently the most common
therapy employed for NMIBC. Since its advent in 1976 [3],
BCG has been extensively used to reduce recurrence and
progression of NMIBC in an attempt to preserve the bladder.
BCG therapy results in 50–60% eﬀectiveness against small
residual tumors and a 70–75% complete response rate for
carcinoma in situ. Adjuvant intravesical therapy was noted
by the 2007 American Urological Association (AUA) panel
to reduce recurrences by 24% and treatment with BCG was
recommendedbythepanel.Unfortunately,ahighpercentage
of patients fail initial BCG therapy and 40–50% of BCG
responders develop recurrent tumors within the ﬁrst 5 years
[2]. In addition, up to 90% of patients experience some
sort of side eﬀects including, although rare, life-threatening
complications such as sepsis.
According to the AUA’s 2007 clinical practice guidelines,
BCGtherapyshouldbeinitiatedtwotothreeweeksfollowing
TURBT with a classic course consisting of six weekly
intravesical installations. Lyophilized powder BCG (81mg
corresponding to 1–5 × 108 colony-forming units of viable
mycobacteria) is reconstituted in 50mL of saline and admin-
istered via urethral catheter into an empty bladder with2 Clinical and Developmental Immunology
a dwell time of 2 hours. Maintenance BCG is more eﬀective
in decreasing recurrence as compared to induction therapy
alone. Multiple meta-analyses support BCG maintenance
and it is now ﬁrmly established in clinical practice. The
European Association of Urology (EAU) and the AUA rec-
ommend one year of maintenance for high-risk patients
[4, 5]. An optimal schedule/duration of therapy has yet
to be determined; however, most who use maintenance
follow some permutation of the Southwest Oncology Group
(SWOG) program, a 3-week “mini” series given at intervals
of 3, 6, 12, 18, 24, 30, and 36 months [6]. At our own
institution, induction (ﬁrst BCG therapy) is initiated 2 to
3 weeks following TURBT with 6 weekly installations and
a 1-2 hour dwell time. For patients with carcinoma in situ,
severe dysplasia, Grade 3/high grade or poorly diﬀerentiated
pathology, and/or stage T1 disease, formal restaging under
anesthesia is performed 6 weeks later including obtaining
bilateral upper tract cytology, retrograde pyelograms, 4-5
random bladder biopsies, and prostatic urethral biopsies. If
this pathology and restaging is negative, maintenance cycles
may be initiated in 6 weeks. We classify three maintenance
cycles A, B, and C. Maintenance A consists of 3 weekly
instillations followed by cystoscopy 6 weeks later. Cytology
and ﬂuorescence in situ hybridization (FISH) in urine spec-
imens may be obtained at this time. If cystoscopy/cytology
is negative, maintenance B may be initiated 6 months after
the conclusion of cycle A, again for 3 weekly treatments.
Maintenance C is initiated 6 months after the conclusion of
cycle B. Following cycle C, cystoscopy/cytology is repeated
every 3 months for 2 years from the original diagnosis at
which time it is extended to every 6 months for 1 year, and
then annually.
2. Mechanism of BCG Action
Since its ﬁrst therapeutic application in 1976, major eﬀorts
have been made to decipher the mechanisms through which
BCG mediates antibladder cancer immunity [7, 8]. During
the past decades, many details of the molecular and cellular
mechanisms involved have been discovered although the
exact mechanisms of BCG action still remain elusive. It is
now accepted that a functional host immune system is a
necessary prerequisite for successful BCG immunotherapy.
It has also become clear that the eﬀects of intravesical
BCG depend on the induction of a complex inﬂammatory
cascade event in the bladder mucosa reﬂecting activation
of multiple types of immune cells and bladder tissue
cells [7, 8]. After instillation, BCG adheres to ﬁbronectin
on the urothelial lining through a ﬁbronectin attachment
protein (FAP) on BCG [9]. This interaction between BCG
and the urothelium is one of the ﬁrst and most crucial
steps. Attached BCG is then internalized and processed by
urothelial cells including urothelial carcinoma cells (UCCs),
resulting in secretion of an array of proinﬂammatory
cytokines and chemokines such as interleukin (IL)-1, IL-
6, IL-8, tumor necrosis factor (TNF)-α,a n dg r a n u l o c y t e -
macrophage colony stimulating factor (GM-CSF) [10, 11].
Following urothelial cell activation, an inﬂux of various
leukocyte types into the bladder wall occurs including
neutrophils, monocytes/macrophages, lymphocytes, natural
killer (NK) cells, and dendritic cells (DCs) [12–14]. These
inﬁltrating leukocytes are activated and produce a variety of
additional proinﬂammatory cytokines and chemokines and
also form BCG-induced granuloma structures in the bladder
wall [12, 14]. Subsequently, a large number of leukocyte
types such as neutrophils, T cells, and macrophages are
expelled into the bladder lumen and appear in patients’
voided urine [15–18]. In addition, transient massive cy-
tokines and chemokines can be detected in voided urine
including IL-1β, IL-2, IL-6, IL-10, IL-12, IL-18, interferon
(IFN)-γ,T N F - α, GM-CSF, macrophage colony-stimulating
factor (M-CSF), macrophage-derived chemokine (MDC),
monocyte chemoattractant protein (MCP)-1, macrophage-
inﬂammatory-protein- (MIP-) 1α, interferon-inducible pro-
tein (IP)-10, monokine induced by γ-interferon (MIG), and
eosinophil chemoattractant activity (Eotaxin) [17, 19–24].
The urine of animals treated with intravesical BCG also
showed increased IL-1α,I L - 1 β, IL-2, IL-3, IL-4, IL-5, IL-6,
IL-10, IL-12, IL-17, IFN-γ,T N F - α, GM-CSF, M-CSF, and
MIP-1α, regulated on activation normal T cell expressed and
secreted (RANTES), and keratinocyte-derived chemokine
(KC) [14]. It has been noted that the development of a
predominant Th1 cytokine proﬁle (e.g., IFN-γ, IL-2, and IL-
12) is associated with the therapeutic eﬀects of BCG, whereas
the presence of a high level of Th2 cytokines (e.g., IL-10)
is associated with BCG failure [20, 22, 23]. Thus, a shift of
the cytokines produced towards a Th1 milieu is necessary
for succesful BCG immunotherapy of bladder cancer. To
support this, it has been observed that both IFN-γ and IL-
12 but not IL-10 are required for local tumor surveillance
in an animal model of bladder cancer [25]. Mice deﬁcient
in IL-10 genetically (IL-10−/−) or functionally via antibody
neutralization can also develop enhanced antibladder cancer
immunity in response to intravesical BCG [23].
Multiple immune cell types participate in the inﬂam-
matory response induced by BCG in the bladder. It is well
accepted that macrophages, an indispensable cellular com-
ponent of the innate immune system, serve as the ﬁrst line of
defense in mycobacterial infection. Activation, maturation,
and cytokine production of macrophages are primarily
induced by Toll-like receptor (TLR) 2 ligation [26]. Follow-
ing BCG instillation, an increased number of macrophages
can be observed in bladder cancer inﬁltrates and the per-
itumoral bladder wall. Voided urine after BCG instillation
also contains an increased number of macrophages and
the cytokines and chemokines predominantly produced by
m a c r o p h a g e ss u c ha sT N F - α, IL-6, IL-10, IL-12, and IL-
18 [15, 17, 19, 22–24]. In addition to presenting BCG
antigens, both human and murine macrophages are capable
of functioning as tumoricidal cells toward bladder cancer
cells upon activation by BCG in vitro [27–31]. The killing
of bladder cancer cells by macrophages relies on direct
cell-to-cell contact and release of various soluble eﬀector
factors such as cytotoxic cytokines TNF-α and IFN-γ and
apoptotic mediators such as nitric oxide (NO) [29–32]. Th1
cytokines(e.g.,IFN-γ)enhancetheinductionofmacrophage
cytotoxicity whereas Th2 cytokines (e.g., IL-10) inhibit the
induction of macrophage cytotoxicity [30, 31].Clinical and Developmental Immunology 3
Neutrophils also compose the early responding cells to
BCG instillation of the bladder and can be observed in the
bladder wall and urine shortly after BCG instillation [14,
15, 17, 18]. Neutrophils are central mediators of the innate
immunity in BCG infection and are activated by signalling
through TLR2 and TLR4 in conjunction with the adaptor
protein myeloid diﬀerentiation factor 88 (MyD88) [33].
In addition to secretion of proinﬂammatory cytokines and
chemokines(e.g.,IL-1α,IL -1β,IL -8,MIP -1α,MIP -1β,MCP -
1, transforming growth factor (TGF)-β, and growth-related
oncogene (GRO)-α) that lead to the recruitment of other
immune cells [34], recent studies revealed that neutrophils
are the primary source of TNF-related apoptosis-inducing
ligand (TRAIL) found in the urine after BCG instillation
[35, 36]. TRAIL is a member of the TNF family that induces
apoptosis in malignant cells but not in normal cells. Studies
have indicated that the neutrophil TRAIL response is spe-
ciﬁc to BCG stimulation rather than nonspeciﬁc immune
activation. Studies have also revealed a positive correlation
between urinary TRAIL level and the therapeutic eﬀects
of BCG, as BCG responders contained a signiﬁcant higher
amount of urinary TRAIL than BCG nonresponders [35].
These observations suggest an important role of neutrophils
in BCG-induced antibladder cancer immunity. Indeed, it
has been observed that depletion of neutrophils resulted in
a reduced BCG-induced antibladder cancer response in a
mouse model of bladder cancer [34].
Following the activation of macrophages and neutrophils
in the bladder wall, driven by chemoattractants, recruitment
of other immune cell types including CD4+ T cells, CD8+ T
cells,NKcells,andDCtakesplace[12,13].Asforneutrophils
and macrophages, these cell types can be found in the
voidedurineofpatientsafterBCGinstillation[15–17].These
eﬀector cells produce various cytokines and chemokines to
further promote BCG-induced antibladder cancer immune
responses in the local milieu. In addition, DC, together
with macrophages, trigger an anti-BCG-speciﬁc immune
response via antigen presentation to T cells that also ampli-
ﬁes the BCG-induced antitumor immunity. Like neutrophils
and macrophages, both T cells and NK cells are cytotoxic
toward bladder cancer cells upon activation. They kill target
cells via the major histocompatibility complex (MHC)
restricted (e.g., for cytotoxic T lymphocytes (CTL)) and/or
MHC nonrestricted pathways (e.g., for NK cells) [27, 37,
38]. Perforin-mediated lysis and apoptosis-associated killing
(e.g., via Fas ligand and TRAIL) have been implicated as
the major molecular eﬀector mechanisms underlying the
eradication of bladder cancer cells. These eﬀector cell types
are crucial for BCG immunotherapy of bladder cancer,
as depletion of these cell types failed to develop eﬀective
antibladder cancer responses in vivo and kill bladder cancer
cells in vitro [39, 40].
It has been shown that stimulation of human peripheral
blood mononuclear cells (PBMCs) by viable BCG in vitro
leads to the generation of a specialized cell population
called BCG-activated killer (BAK) cells [41, 42]. BAK cells
are a CD3−CD8+CD56+ cell population whose cytotoxicity
is MHC nonrestricted [42, 43]. BAK cells kill bladder
cancercells through the perforin-mediated lysis pathway and
eﬀectively lyse NK cell-resistant bladder cancer cells [41–
43]. Macrophages and CD4+ T cells have been found to be
indispensable for the induction of BAK cell killing activity
b u th a v en os u c ha c t i v i t yb yt h e m s e l v e s[ 42]. Th1 cytokines
IFN-γ and IL-2 have also been found to be required for the
induction of BAK cell cytotoxicity, as neutralizing antibodies
speciﬁc to these cytokines could inhibit BCG-induced cyto-
toxicity [42]. BAK cells, together with lymphokine-activated
killer (LAK) cells, a diverse population with NK or T-cell
phenotypes that are generated by IL-2 [44, 45], have been
suggested to be the major eﬀector cells during intravesical
BCG immunotherapy of bladder cancer. Other potential
cytotoxic eﬀector cells include CD1 restricted CD8+ Tc e l l s
[46],γδ Tcells[47],andnaturalkillerT(NKT)cells[47,48].
Activation of the innate immune system is a prereq-
uisite for the BCG-induced inﬂammatory responses and
the subsequent eradication of bladder cancer by intravesical
BCG. In BCG instillation, TLRs participate in neutrophil,
macrophage and DC maturation and activation. Both TLR2
and TLR4 appear to serve important but distinct roles
in the induction of host immune responses to BCG or
BCG cell-wall skeleton [26]. Like other microbes, BCG has
surface components called pathogen-associated molecular
patterns (PAMPs) that are recognized by cells of the innate
immune system through TLRs during infection [49]. It is
this interaction between TLRs and PAMPs that activates
the cells of the innate immune system, leading to BCG-
inducedinﬂammatoryresponsesandsubsequenteradication
of bladder cancer. It is known that the antitumor eﬀect
of intravesical BCG depends on its proper induction of
a localized Th1 immune response. However, a systemic
immune response also appears involved in intravesical BCG
therapy. It has been reported that puriﬁed protein derivative
(PPD) skin test often converts from negative to positive
after BCG instillation and the eﬀective treatment is associ-
ated with the development of delayed-type hypersensitivity
(DTH) reaction to PPD [50]. Animal studies have also
demonstrated the importance of DTH in the antitumor
activity of intravesical BCG therapy [23]. Moreover, studies
have shown increased levels of cytokines and chemokines in
the serum (e.g., IL-2, IFN-γ, MCP-1, and RANTES), along
with production of these cytokines and chemokines in the
urine and/or bladder, during the course of BCG instillation
[21,51].Furthermore,studieshavealsoshownanincreasein
PBMC cytotoxicity against UCC after BCG instillation [21].
In addition to the ability of BCG to elicit host immune
responses, evidence supports a direct eﬀect of BCG on the
biology of UCC. In vitro studies have shown that BCG
is antiproliferative and even cytotoxic to UCC [27, 52]
and induces UCC expression of cytokines and chemokines
(e.g., IL-1β, IL-6, IL-8, TNF-α,a n dG M - C S F )[ 11], antigen-
presenting molecules (e.g., MHC class II, CD1 and B7-
1) [53], and intercellular adhesion molecules (e.g., ICAM-
1) [53]. Analysis of tumor biopsy specimens from bladder
cancer patients who underwent intravesical BCG therapy
further supported the ability of BCG to induce UCC
expression of these molecules in vivo [13]. Moreover, the
bladder urothelium of animals treated with intravesical
BCG shows upregulation of HLA antigens (e.g., MHC class4 Clinical and Developmental Immunology
I and II) and changes of many other molecules [54]. Recent
studies have revealed that by cross-linking α5β1 integrin
receptors, BCG exerts its direct biological eﬀects on UCC,
including activation of the signal transduction pathways
involving activator protein (AP) 1, NFκB and CCAAT-
enhancer-binding protein (C/EBP) [55], upregulation of
gene expressions such as IL-6 and cyclin dependant kinase
inhibitor p21 [55, 56], and cell cycle arrest at the G1/S
transition [57]. Although some studies showed the ability
of BCG to induce apoptosis in UCC [58], other studies
demonstratedthatBCGinducednoapoptosisorevencaused
apoptotic resistance in UCC [59]. Further studies revealed
that BCG induced UCC death in a caspase-independent
manner [59] and that p21 played an important role in
modulating the direct eﬀects of BCG on UCC [60].
3. Combination of BCG with Th1 Cytokines for
Bladder Cancer Treatment
The proper induction of Th1 immunity is required for
successful BCG immunotherapy of bladder cancer. Since a
high percentage of patients do not respond to BCG and the
eﬀect of BCG is associated with signiﬁcant toxicity, strategies
to combine BCG with recombinant (r) Th1 cytokines to
enhance BCG therapeutic eﬃcacy while reducing BCG toxi-
city have been employed and studied. Among Th1 cytokines,
rIFN-α is most extensively studied and has been shown to
be safe and tolerable when used intravesically, alone or in
combination with BCG, in many controlled studies [61–65].
The side-eﬀect proﬁle of combination therapy is similar to
BCG monotherapy including lower urinary tract symptoms
such as frequency, urgency, dysuria, bladder spasm, and
hematuria. Systemic fever, ﬂu-like symptoms, and myalgias
were found in <25% of patients and were self-limited.
Beneﬁts have been seen in patients with BCG failures [61–
63]. Treatment with low-dose BCG (1/3 or 1/10 the standard
dose) combined with rIFN-α resulted in 45–53% of patients
who had failed prior BCG monotherapy to remain disease-
free at 24-month median followup [61, 63]. The beneﬁt in
na¨ ıve patients is currently in question with recent studies
showingmixedresults.APhaseIIIstudysuggestednobeneﬁt
in BCG na¨ ıve patients [64]. However, no subgroup analysis
was performed for carcinoma in situ or high-risk patients.
Therefore, it can still be concluded that the BCG-rIFN-
α combination therapy may provide a beneﬁt to patients
with high-risk disease or carcinoma in situ. Data since the
release of the Phase III study supports the combination
therapy with BCG and rIFN-α in BCG na¨ ıve patients [65].
Thus, more studies are needed to formally determine the
eﬀect of the combination therapy for BCG naive patients.
To date, a combination therapy with BCG and rIFN-α2B
has been employed, particularly for patients with previous
BCG failures, those with carcinoma in situ, and the elderly
[63]. Optimal dose and schedule have yet to be deﬁned in
controlled trials and debate continues on the subject. At
our institution, we use the standard dose of TICE BCG
plus 50 million units (MU) of rIFN-α2B intravesically as
induction therapy for BCG na¨ ıve patients. For BCG exposed
patients, 1/3 the standard dose of BCG plus 50 MU of rIFN-
α2B is utilized. The dose may be lowered for those patients
experiencing lower urinary tract symptoms or low grade
fever. For maintenance cycle A, we adjust the BCG dose
for week 1 consisting of 1/3 the standard dose of BCG plus
50MU of rIFN-α2B. For weeks 2 and 3, the BCG dose is
lowered to 1/10 the standard dose plus 50MU of rIFN-α2B.
Maintenance cycles B and C utilize similar dosing.
Other cytokines that have been used intravesically
include rIL-2, rIL-12, rIFN-γ, and rGM-CSF. A study
demonstrated that intravesical rIL-2 was beneﬁcial for
patients with T1 papillary bladder carcinoma after TURBT
showing regression of marker lesions and lack of major toxic
eﬀects[66].OtherstudiesalsodemonstratedintravesicalrIL-
2 to be feasible, safe, and eﬀective in patients with NMIBC
who were untreated or had failed prior intravesical therapy
with other agents [67, 68]. A study demonstrated thatintrav-
esical rIL-12 was well tolerated by patients with recurrent
NMIBC but showed no clinically relevant antitumor and
immunologic eﬀects [69]. However, the maximum tolerated
dose of rIL-12 was not reached in the study. Diﬀerent
from human studies, animal studies showed encouraging
results. A survival advantage of intravesical rIL-12 was
observed in a mouse orthotopic bladder cancer model [70].
Further studies for intravesical rIL-12 use are warranted. For
intravesical rIFN-γ, a study showed the absence of major
toxicity and the therapeutic eﬀect superior to mitomycin C
for patients with NMIBC who underwent TURBT [71]. In
addition, populations of leukocytes in the urothelium were
signiﬁcantly increased in rIFN-γ-treated patients conﬁrm-
ing its induction of localized cellular immune responses.
Other studies also supported the safety and antitumor
activity of intravesical rIFN-γ monotherapy [72]. Studies
also demonstrated that intravesical rGM-CSF was eﬀective
as a prophylactic therapy for patients with NMIBC after
TURBT [73, 74]. In correlation with regression of marker
lesions, intravesical rGM-CSF induced leukocyte migration
and activation in the bladder mucosa. Despite all these
observations, however, single cytokine therapy has only been
evaluatedinsmallnumbersofpatientsandhasnotyetshown
compelling results in general. Indeed, in vitro studies have
demonstrated that cytokines IL-2, IL-12, and TNF-α,l i k e
IFN-α, can enhance BCG for the induction of Th1 immune
responses in human PBMC [75–77]. Thus, addition of these
cytokines to BCG may provide beneﬁts for BCG therapy
particularly for BCG nonresponders or relapsers. Studies are
absolutely needed to examine the combination of BCG with
these cytokines for the treatment of bladder cancer.
4. Advances in GeneticEngineeringof BCG for
CytokineDelivery
4.1. BCG as a Heterologous Gene Delivery Vehicle. Because of
itsuniquecharacteristics,suchasadjuvantpotential,lowtox-
icity, and potent immunogenicity, BCG has long been con-
sidered to be an attractive live vaccine delivery vehicle with
which to deliver protective antigens of multiple pathogens.
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of mycobacterial genetics and molecular biology, a wide
range of rBCG vaccine candidates expressing bacterial, viral,
parasitic antigens have been developed including those for
Mycobacterium tuberculosis (M.tb), human immunodeﬁ-
ciency virus (HIV), and hepatitis B and C viruses [78]. As
early as in the 1980s, studies showed that mycobacteria were
capable of delivering foreign genes that were introduced into
the microbes [79, 80]. In the early 1990s, vectors carrying
strong promoters from the mycobacterial major heat-shock
protein genes (e.g., hsp60 and hsp70) and unique cloning
sites,whichallowedextrachromosomalorintegrativeexpres-
sionofforeignantigens,weredeveloped[81,82].Usingthese
expression vectors, BCG was further demonstrated to be an
eﬀective live delivery vehicle for foreign antigens [81, 83–87].
These rBCG strains constitutively expressed foreign antigens
and elicited long-lasting speciﬁc humoral and/or cellular
immune responses in mice. Some of these rBCG strains even
generated protective immunity against respective pathogens
whose antigens were expressed by mycobacteria such as the
outer surface protein A (OspA, Borrelia burgdorferi)[ 83],
surface proteinase gp63 (Leishmania spp)[ 85], and surface
protein A (Streptococcus pneumoniae)[ 86]. During that time
period, vectors permitting surface expression of foreign
antigens in mycobacteria or secretion from mycobacteria
were also developed [83, 88]. Infection with these rBCG
strains led to enhanced immune responses to some antigens
in mice [83, 86, 89]. Meanwhile, vectors with various
mycobacterial gene promoters, such as α-antigen, PAN,
ag85b, 18kDa, and furA (among many others), were also
developed and demonstrated to be eﬀective to elicit speciﬁc
immune responses and/or protective immunity in diﬀerent
animal species including mouse, guinea pig, hamster, pig,
sheep, rabbit, and monkey [78, 88, 90–92]. In addition,
progress has continued in the reﬁnement of the safety and
eﬃcacy of the rBCG vaccine vehicles. To date, numerous
improved systems employed to express heterologous genes
in BCG are available. Among them are vectors with limited
replication or auxotrophic complementation for safe use in
HIV-infected individuals, capability to replicate at a high-
copy number for increased antigen delivery, dual expres-
sion cassettes for multivalent antigen delivery, capability to
integrate into the genome at multiple sites for diﬀerential
antigen expression, inducible elements for controlled gene
expression, and expression of perfringolysin or listeriolysin
(with or without urease C gene deletion) for increased CD8+
T-cell stimulation. Although clinical use of rBCG vaccines
is still in an early stage, studies have already demonstrated
that rBCG is safe and eﬀective in humans such as those
expressing OspA and M.tb antigen 85B (Ag85B). In the years
to come, more rBCG vaccines will be evaluated clinically and
their usefulness in preventing human infectious dieases will
become clear.
In addition to a wide range of bacterial, viral, and par-
asitic antigens, BCG has also been engineered to deliver
tumor-associated antigens. For example, BCG expressing
prostate speciﬁc molecules such as prostate speciﬁc antigen
(PSA) and prostate speciﬁc membrane antigen (PSMA)
have been developed. Mice immunized with the rBCG-PSA
or rBCG-PSMA strain developed antigen-speciﬁc immune
responses, primarily a cellular immune response [93]. We
also independently developed a rBCG strain that secretes
the full-length PSA. We observed that mice immunized with
the rBCG-PSA strain, but not a control BCG strain carrying
an empty vector, developed a potent speciﬁc CTL activity
against PSA-expressing RM11psa cells (our unpublished
observations). In addition, we further observed that mice
primed with the rBCG-PSA strain and boosted with Ad-
PSA, a replication-defective adenoviral vector carrying the
full-length PSA coding sequence [94], developed enhanced
PSA-speciﬁc CTL activity and IFN-γ expressing CD4+ and
CD8+ Tcells(ourunpublishedobservations).Severalstudies
including ours have also demonstrated that BCG could be
engineered to express mucin-1 (MUC1), a candidade tumor-
associated antigen for breast cancer and other epithelial
adenocarcinomas, in a manner of multiple tandem repeats
withcoexpressionofIL-2,GM-CSF,orCD80[95–99].Severe
combined immunodeﬁcient (SCID) mice reconstituted with
human peripheral blood lymphocytes (PBLs) followed by
immunization with these MUC1-expressing rBCG strains
developed speciﬁc protective immunity against MUC1-
positive human breast cancer xenografts. These observations
warrant further studies in rBCG delivering tumor antigens
for the treatment of malignant diseases.
Studies have shown that BCG delivery of certain bio-
logically active molecules can induce enhanced immune
responses.AstudydemonstratedthatarBCGstrainsecreting
cathepsin S, a cysteine endoprotease involved in MHC class
II antigen presentation, could restore intracellular cathep-
sin S activity and improve the capacity of BCG-infected
macrophages to stimulate CD4+ T cells [121]. A study
also demonstrated that mice simultaneously immunized
with intraperitoneal ovalbumin (OVA) and intranasal rBCG
secreting the assembled pentameric cholera toxin B subunit
developed a long-lasting OVA-speciﬁc mucosal IgA response
as well as a systemic IgG response [122]. Remarkably, a
rBCG strain expressing the genetically detoxiﬁed S1 subunit
of pertussis toxin (S1PT) showed enhanced BCG adjuvant
potential and, when administered intravesically, resulted in
bladder weight reduction and increased survival time in
a mouse syngeneic orthotopic tumor model [123, 124].
Moreover, BCG has also been engineered to express the
model antigen OVA for studies of the mechanisms under-
lying BCG induction of antigen-speciﬁc immune responses
[125]. These studies revealed that the ability of BCG to
induce a delayed but persistent immune response was due
to its chronicity in infection that led to a long eﬀector phase
and reduced immune cell attrition compared to Listeria
monocytogenes (an acute pathogen). Furthermore, we and
othershavealsoengineeredBCGtoexpress greenﬂuorescent
protein (GFP), either alone or in combination with antigenic
molecules(e.g.,OVA)orcytokines(e.g.,IL-2),forthestudies
of BCG traﬃcking, antigen deliver, and antimycobacterial
infection [109, 126, 127].
4.2. Th1 Cytokine-Secreting rBCG. In our early studies, we
developed a panel of rBCG strains that secreted mouse
IL-2 or rat IL-2 under the control of the mycobacte-
rial hsp60 promoter and α-antigen signal sequence [100].6 Clinical and Developmental Immunology
Table 1: Cytokine- and chemokine-expressing rBCG strains.
Strain Cytokine Species Immunological eﬀect Reference
IL-2 BCG (RBD) IL-2 m Th1 cyt prod, Antitumor, Cytotoxicity [30, 100, 101]
IL-2 BCG (MAO) IL-2 r Th1 cyt prod [100]
BCG-CI IL-2 h Anti-BCG [102]
BCG-CII IL-2 h Anti-BCG [102]
BCG-IL-2 IL-2 m CI, Th1 & Th2 cyt prod [103]
BCG-GM-CSF GM-CSF m CI, Th1 & Th2 cyt prod, DC act, Anti-M.tb [103, 104]
BCG-IFN-γ IFN-γ m CI, Th1 & Th2 cyt prod, Anti-BCG [103, 105]
rBCG/IL-2 IL-2 m CI, Th1 cyt prod, Anti-BCG [106–108]
rBCG-IL-2/GFP IL-2 m CI, Th1 cyt prod, Anti-BCG [109]
rBCG (α-Ag-IL-2) IL-2 m Th1 cyt prod, Cytotoxicity [28]
BCG-IFN-γ IFN-γ m Th1 cyt prod, Anti-BCG [110]
rBCG-IFN-α IFN-α 2B h Th1 cyt prod, Cytotoxicity [38, 111, 112]
rBCG/IL-18 IL-18 m no clear eﬀect [108]
BCG IL-18 IL-18 m Th1 & Th2 cyt prod [113, 114]
BCG-hIL2MUC1 IL-2 h CI, Th1 cyt prod, Antitumor [95, 96]
rBCG-IFN-γ IFN-γ m CI, Th1 cyt prod, Antitumor [115]
rBCG-IL-18 IL-18 m Th1 cyt prod, Anti-BCG, Cytotoxicity [29, 30]
rBCG-huIL-2-ESAT6 IL-2 h CI, Th1 cyt prod, Cytotoxicity, HI [116]
rBCG-IL-2 IL-2 h Th1 cyt prod [112]
BCGMCP-3 MCP-3 m CI, Anti-BCG [117]
rBCG-AEI IFN-γ m CI, HI, Anti-M.tb [118]
rBCG-Ag85B-IL15 IL-15 m CI, Th1 cyt prod, Anti-M.tb [119]
rBCG-MVNTR4-CSF GM-CSF h CI, Th1 cyt prod, Antitumor [97, 99]
rBCG-MVNTR8-CSF GM-CSF h CI, Th1 cyt prod, Antitumor [97, 99]
rBCG-Ag85B-Esat6-TNF-α TNF-α mC I , H I [ 120]
Anti-BCG: anti-BCG infection; Anti-M.tb: anti-Mycobacterium tuberculosis infection; CI: cellular immunity; DC act: dendritic cell activation; h: human; HI:
humoral immunity; m: mouse; r: rat; Th1 cyt prod: T helper type 1 cytokine production; Th2 cyt prod: T helper type 2 cytokine production.
We demonstrated that the IL-2 secreting rBCG strains
induced enhanced IFN-γ production by mouse splenocytes
in vitro compared to wild-type BCG. Since then, numer-
ous rBCG strains secreting diﬀerent mouse and human
cytokines, primarily Th1 cytokines (e.g., IL-2, IL-18, IFN-
γ,a n dI F N - α), have been developed (Table 1). In addition,
rBCG strains secreting other cytokines or chemokines (e.g.,
GM-CSF, IL-15, TNF-α, and MCP-3) have also emerged.
Most of these cytokine- and chemokine-secreting rBCG
strains showed their abilities to enhance BCG-induced cel-
lular immune responses including Th1 cytokine production,
cellular cytotoxicity, DC activation, and anti-BCG or anti-
M.tb infection. Some of them even showed their antitumor
eﬀects in animal models of melanoma [101], breast cancer
[96, 97, 99], and bladder cancer [115]. Certain cytokine-
secreting rBCG strains also induced humoral immune
responses and Th2 cytokine production other than cellular
immune responses in vitro and in vivo.
5.Th1 Cytokine-SecretingrBCGin
Cancer Treatment
5.1. Antitumor Studies. BCG is a potent immunoadjuvant
and induces a Th1 predominant immune response that is
required for eﬀective tumor eradication in most can-
cer types. Genetic manipulation of BCG to secrete Th1-
stimulating cytokines with simultaneous coexpression of
tumor-associated antigens may therefore potentiate the in-
duction of speciﬁc antitumor immune responses. This strat-
egy has been approached since the emergence of cytokine-
secreting rBCG strains in the 1990s. Early studies demon-
strated that mouse IL-2 secreting rBCG was at least equally
eﬀective to wild-type BCG when used as an intratumoral
injection or a vaccine therapy in conjunction with irradiated
tumor cells in a mouse melanoma model [101]. However,
it was not until recently that the potential of rBCG for
treating cancer has gained further appreciation. We and
others have developed rBCG strains that deliver the breast-
cancer-associated antigen MUC1 in a form of multiple
tandem repeats with coexpression of human IL-2 or human
GM-CSF [95–97, 99]. SCID mice reconstituted with human
PBL followed by immunization with the rBCG strains
developed MUC1-speciﬁc cellular immune respnses and
enhanced protection against MUC1-positive human breast
cancer xenografts compared to control mice reconstituted
withhumanPBLandimmunizedwithnoncytokinesecreting
BCG. Studies have also demonstrated that the antitumor
eﬀects of the rBCG strains were correlated with the number
of MUC1 tandem repeats delivered by BCG [97, 99]. TheseClinical and Developmental Immunology 7
results suggest that these MUC1 rBCG strains coexpressing
Th1-stimulatingcytokinesarepromisingcandidatesasbreast
cancer vaccines and thus deserve further investigation.
5.2. Antibladder Cancer Studies. Intravesical BCG is cur-
rently the treatment of choice for NMIBC. As for most other
cancer types, the proper induction of a cellular immune
response is required for successful BCG immunotherapy
of bladder cancer. Studies have demonstrated that Th1
cytokine-secreting rBCG strains are capable of inducing
enhanced cellular immune responses, leading to eﬀective
protection against mycobacterial infection (e.g., M.tb)a n d
tumor progression (e.g., breast cancer) in various animal
models. Unfortunately, studies on rBCG for treating bladder
cancer are currently underdeveloped and, up to date, only
a few reports have been available. However, studies have
demonstrated that Th1 cytokine-secreting rBCG strains are
superior to noncytokine secreting BCG for the induction of
antibladder cancer immune responses in vitro and in vivo.
5.2.1. In Vitro Studies. It has been known that BCG stimula-
tion of human PBMC leads to the generation of eﬀector cells
cytotoxic to bladder cancer cells in vitro [41, 42]. We recently
demonstrated that stimulation of human PBMC with rBCG-
IFN-α, a rBCG strain secreting human IFN-α2B [111],
in vitro for 7 days induced enhanced PBMC cytotoxicity
toward human bladder cancer cell lines T24, J82, 5637,
TCCSUP, and UMUC-3 by up to 2-fold compared to control
BCG carrying an empty vector [38]. This induction of
enhanced PBMC cytotoxicity was correlated with increased
production of IFN-γ, and IL-2 by rBCG-stimulated PBMC.
Studies further revealed that this enhancement in PBMC
cytotoxicity was dependent on BCG secreted IFN-α as well
as endogenously expressed IFN-γ and IL-2, as blockage of
IFN-α,I F N - γ or IL-2 by neutralizing antibodies during
BCG stimulation reduced or abolished the induction of this
enhanced PBMC cytotoxicity. Studies using NK and CD8+
T cells isolated from human PBMC revealed that both cell
types were responsible for the enhanced PBMC cytotoxicity
induced by rBCG-IFN-α with the former cell type being
more predominant.
An early study demonstrated that human peripheral
monocytes/macrophages were capable of functioning as
tumoricidal cells toward bladder cancer UCRU-BL-17 cells
upon activation by BCG in vitro [27]. It was observed that
the cytotoxic activity of human monocytes/macrophages
was signiﬁcantly enhanced after BCG stimulation, while
the na¨ ıve cells exhibited only minimum cytotoxicity. Later,
more studies including ours further demonstrated that
mouse macrophages could also function as tumoricidal
cells toward bladder cancer cells upon activation by BCG
in vitro [28–31]. Stimulation of thioglycollate-elicited peri-
toneal macrophages by BCG for 24 hour resulted in
macrophage-mediated killing of bladder cancer MBT-2
(C3H background) and MB49 (C57BL/6 background) cells
in a dose-dependent manner [30, 31]. Studies also revealed
that endogenous Th1 cytokines (e.g., IL-12, IL-18, IFN-
γ,a n dT N F - α) played an important role in BCG-induced
macrophage cytotoxicity, as blockage of these cytokines
during BCG stimulation led to substantially reduced ma-
crophage cytotoxicity toward bladder cancer cells [30]. In
contrast, supplementation of BCG with Th1 cytokines (e.g.,
rIL-2, rIL-12, or rIL-18) increased macrophage cytotoxicity
by approximately 2-fold. Consistent with these observations,
rBCG strains secreting mouse IL-2 or mouse IL-18 showed
enhanced macrophage-mediated killing on bladder cancer
MBT-2 cells, which was correlated with increased expression
ofIFN-γ,TNF-α,andIL-6byrBCG-stimulatedmacrophages
[30]. The eﬀect of mouse IL-2 secreting rBCG strain on the
induction of macrophage cytotoxicity toward bladder cancer
MBT-2 cells was also demonstrated by a separate study [28].
5.2.2. In Vivo Studies. Although the in vitro studies have
suggested the potential usefulness of Th1 cytokine-secreting
rBCG strains for the treatment of bladder cancer, the
eﬀect of rBCG on treating bladder cancer in vivo has
not well been studied. Up to date, only an rBCG strain
secreting mouse IFN-γ (rBCG-IFN-γ) has been studied
in a mouse MB49 syngeneic orthotopic tumor model
[115]. This study showed that, with a low-dose treatment
regimen, intravesical administration of rBCG-IFN-γ signif-
icantly prolonged animal survival compared to medium-
treated controls, whereas BCG carrying an empty vector
only slightly increased survival. In a similar experiment
using the MB49 syngeneic orthotopic tumor model in IFN-
γ knockout mice, intravesical treatment with rBCG-IFN-γ
failed to prolong survival of mice, indicating that rBCG-
derived IFN-γ had no measurable antitumor eﬀect in the
absence of endogenous IFN-γ. Studies also provided the
mechanismsunderlyingtheeﬀectofrBCG-IFN-γ ontreating
bladder cancer. As demonstrated, this rBCG-IFN-γ strain
could speciﬁcally upregulate the expression of MHC class
I molecules on MB49 cells in vitro compared to control
BCG, as the MHC class I upregulation could be blocked
by an inhibitory antibody to IFN-γ. This rBCG strain also
enhanced recruitment of CD4+ T cells into the bladder
and further induced the local expression of IL-2 and IL-4
mRNA compared to control BCG. In addition, we have also
evaluated the eﬀects of rBCG strains secreting mouse IL-
2 or mouse IP-10 (a Th1 chemokine) on treating bladder
cancer in the MB49 syngeneic orthotopic tumor model
and observed survival beneﬁts of these rBCG strains (our
unpublished observations). All these observations suggest
that rBCG strains secreting Th1 cytokines or chemokines
possess improved antitumor properties and may oﬀer new
opportunities for the treatment of bladder cancer.
Supporting Th1 cytokine-secreting rBCG, Mycobac-
terium smegmatis (M. smegmatis), a closely related non-
pathogenic mycobacterial organism, has been engineered
to secrete mouse TNF-α (M. smegmatis/TNF-α)a n dt e s t e d
in a transplantable MB49 tumor model [128]. Studies
demonstrated that lymphocytes from tumor-bearing mice
vaccinated with M. smegmatis/TNF-α produced elevated and
prolonged IFN-γ but no IL-10 in response to mycobacterial
antigen or tumor lysate stimulation in vitro. Histopathology
revealed signiﬁcantly increased inﬁltrating CD3+ lympho-
cytesinthetumornodulesofmicereceivingtherecombinant8 Clinical and Developmental Immunology
vaccine compared to those of mice receiving wild-type
bacteria. These observations indicated that M. smegmatis
/TNF-α induced cell-mediated immunity. Importantly, mice
implanted subcutaneously with MB49 tumor and treated at
an adjacent site with the recombinant vaccine exhibited sig-
niﬁcantly reduced tumor growth with a 70% durable tumor-
free survival compared to those treated with wild-type bac-
teria or BCG (a 10–20% long-term survival). Interestingly,
treatment with M. smegmatis/TNF-α also resulted in similar
tumor growth inhibition in T-cell-deﬁcient athymic nude
miceandreducedbutnotabolishedtumorgrowthinhibition
inNKcell-deﬁcientBeigemice.Theseobservationsindicated
that NK-cells contribute to the antitumor eﬀect of M.
smegmatis/TNF-α but are not solely responsible for the
eradication of tumor. Like immunocompetent mice, Beige
mice also developed tumor-speciﬁc memory after treatment
with M. smegmatis/TNF-α. A study also demonstrated
enhanced immunotherapeutic potential of a human TNF-
α secreting recombinant M. smegmatis for treating bladder
cancer [129]. The ability to deliver immunomodulatory
cytokines with no pathogenic eﬀects makes M. smegmatis
attractive as an alternative intravesical mycobacterial agent
for bladder cancer treatment.
6. Conclusion and FutureView
Intravesical administration of live BCG for superﬁcial blad-
der cancer is the most successful immunotherapy for
solid malignancy. However, BCG therapy is associated with
signiﬁcant toxicity and is ineﬀective in approximately 30–
40% of cases. During the past 2 decades, advances in
mycobacterial genetics and molecular biology have oﬀered
unprecedented opportunities for the development of genet-
ically modiﬁed BCG strains that possess improved safety
proﬁle, immunogenicity, and protective eﬃcacy. Among
these, manipulation of BCG to secrete Th1 cytokines (e.g.,
IL-2, IL-18, IFN-γ,a n dI F N - α), alone or in combination
with coexpression of bacterial or tumor antigens, represents
one of the most attractive strategies for the development of
improved vaccines. These types of rBCG strains have shown
their potential to induce enhanced cellular immunity, lead-
ing to eﬀective protection against mycobacterial infection
(e.g., M.tb) and tumor progression (e.g., breast cancer) in
various animal models. In bladder cancer treatment, BCG is
administered intravesically; therefore, rBCG strains secreting
Th1 cytokines can augment a localized cellular immune
response that is crucial for eﬀective BCG immunotherapy
of bladder cancer. Since intravesical BCG in combination
with local administration of Th1 cytokines such as rIFN-α
has already been used in humans and demonstrated to be
beneﬁcialforbladdercancerpatients,Th1cytokine-secreting
rBCG strains could be very useful as improved BCG agents.
Indeed, these rBCG strains have been demonstrated to be
capable of inducing antibladder cancer immune responses
both in vitro and in vivo in animal studies. Because of their
enhanced immunogenicity, Th1 cytokine-secreting rBCG
strains can be used at a lower dose, potentially reducing
side eﬀects. Further studies should focus on determination
of the clinically relevant eﬀects of rBCG strains relative to
each other and optimization of rBCG dosing and treatment
schedule for each rBCG strain. Application of multiple rBCG
strains should be tested and development of new rBCG
strains continued. Moreover, the mechanisms underlying
rBCG action need to be explored. Furthermore, inﬂuence
of rBCG strains on Th17 and regulatory T (Treg) cells
should be evaluated as the importance of these cell types
in bladder cancer has being emerged. All these eﬀorts
will aﬀord us a better understanding of Th1 cytokine-
secreting rBCG strains and the steps necessary for use of
the rBCG strains for treating bladder cancer. The pace of
this research must be maintained if we are to improve this
gold standard therapy for bladder cancer. Th1 cytokine-
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